This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The purpose of the research study is to determine the safety and effectiveness of high doses of Ursodiol, a ursodeoxycholic acid (UDCA), in the treatment of primary sclerosing cholangitis (PSC). PSC is a chronic liver disease of unknown cause. It is characterized by inflammations and destruction of the hepatic (liver) bile ducts. The disease is slowly progressive and usually leads to cirrhosis, hypertension and liver failure over a 10-15 year period. PSC is one of the most common liver diseases and an important indication for liver transplantation in US adults. The cause of PSC is unknown. In at least 70% of the cases, PSC is associated with inflammatory bowel disease and ulcerative colitis. There are no reports of effective medical therapy for PSC at this time. Traditional treatments for liver disease have not been proven effective in the treatment of PSC. The accumulation of toxic bile acids may be an important mechanism of injury in PSC. Therefore, the rationale for using UDCA in the treatment of PSC includes evidence that it plays an immune modifying role and replaces the bile acid with a less toxic bile acid (UDCA). In a pilot study of patients with PSC, UDCA improved liver enzymes over 24 months of treatment. Another small trial produced tissue improvements in those treated with UDCA. A larger randomized study showed no significant changes in treatment or death endpoints, however, the dose of UDCA was small. The purpose of this study is to determine if treatment with higher doses of UDCA is effective in the treatment of PSC. Patients will be studies for a minimum of four years of follow-up to determine the long term effects of high doses of UDCA. A subjects visits will be held in the GCRC. Medical and physical examinations, blood measurements, and tissue sample collection will be done for all subjects. In addition, other routine diagnostic tests may be performed. Patients will be required to sign separate consent forms for any additional procedures. All tests done during this study will be done according to the standard of care for treatment of patients with PSC. Data will be used to determine the effectiveness of UDCA in high doses for patients with PSC.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000065-45
Application #
7604999
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2006-12-20
Project End
2007-11-30
Budget Start
2006-12-20
Budget End
2007-11-30
Support Year
45
Fiscal Year
2007
Total Cost
$17,909
Indirect Cost
Name
Virginia Commonwealth University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Jones, Robert; Vuky, Jacqueline; Elliott, Tony et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 31:1001-7
Al Hawaj, M A; Martin, E J; Venitz, J et al. (2013) Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 19:409-14
Noureddin, Mazen; Yates, Katherine P; Vaughn, Ivana A et al. (2013) Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58:1644-54
Lo, D J; Anderson, D J; Weaver, T A et al. (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 13:320-8
Poklepovic, Andrew; Youssefian, Leena E; Youseffian, Leena et al. (2013) Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs 31:937-42

Showing the most recent 10 out of 367 publications